MedTrace Logo

PFA 100 Evaluation and Reference Interval HOACNY

NCT06100510 · Status: ENROLLING_BY_INVITATION · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2024-10-03

No results posted yet for this study

Summary

The purpose of this research is to evaluate instrument functionality and develop a reference range of normal data by healthy volunteers.

Conditions

  • Effect of Drug

Interventions

DRUG

Aspirin 325mg

Cohort B will receive one (1) 325 mg aspirin 24 hours prior to their second blood draw.

Sponsors & Collaborators

  • Hematology Oncology Associates of Central New York

    lead OTHER

Principal Investigators

  • Theresa O'Sullivan, BS,MLT(ASCP) · Employee

  • Steven Duffy, MD · Physician

Study Design

Allocation
NON_RANDOMIZED
Purpose
SCREENING
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-02-19
Primary Completion
2024-10-10
Completion
2024-10-10
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06100510 on ClinicalTrials.gov